Valuation: Natera, Inc.

Market Cap 39.3B 34.47B 31.82B 29.41B 55.74B 3,763B 56.85B 383B 149B 1,841B 148B 144B 6,392B P/E 2026 *
-165x
P/E 2027 * -1,181x
Enterprise Value 38.27B 33.57B 30.99B 28.64B 54.28B 3,665B 55.37B 373B 145B 1,793B 144B 141B 6,226B EV / Sales 2026 *
13.7x
EV / Sales 2027 * 11.4x
Free-Float
97.02%
Yield 2026 *
-
Yield 2027 * -
1 day+1.94%
1 week+0.70%
Current month+3.62%
1 month+26.23%
3 months+38.56%
6 months+20.04%
Current year+22.78%
1 week 269.66
Extreme 269.66
288.04
1 month 208.79
Extreme 208.794
288.04
Current year 181
Extreme 181
288.04
1 year 131.81
Extreme 131.8106
288.04
3 years 36.9
Extreme 36.9
288.04
5 years 26.1
Extreme 26.1
288.04
10 years 7.35
Extreme 7.35
288.04
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap.
06-30Sell

General Counsel

-16,800 0.0117%
06-30Sell

Executive/Senior Manager

-3,000 0.0021%
06-25Free

Director

1,905 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
+1.86%+0.70%+73.89%+482.23% 39.3B
+0.16%-3.28%+7.14%+31.87% 22.77B
-2.24%+2.10%-20.83%-37.85% 7.46B
+0.19%-4.10%+14.42%+107.92% 5.16B
+1.88%+2.08%+13.68%+40.82% 2.88B
+6.29%+3.36%-24.05%+1,040.20% 1.95B
+4.14%-2.14%+97.01%-12.53% 1.85B
+0.16%-8.73%+26.76%-24.86% 1.68B
+0.39%-2.03%+20.31%-4.09% 1.62B
+0.79%-2.92%-18.41%-68.97% 1.56B
Average +1.37%-1.05%+18.99%+155.47% 8.62B
Weighted average by Cap. +1.06%-0.36%+37.18%+254.10%

Financials

2026 *2027 *
Net sales 2.8B 2.45B 2.27B 2.09B 3.97B 268B 4.05B 27.24B 10.58B 131B 10.51B 10.28B 455B 3.33B 2.92B 2.69B 2.49B 4.72B 319B 4.81B 32.39B 12.58B 156B 12.49B 12.22B 541B
Net income -224M -197M -181M -168M -318M -21.46B -324M -2.18B -848M -10.5B -842M -823M -36.46B -27.55M -24.16M -22.31M -20.61M -39.07M -2.64B -39.85M -268M -104M -1.29B -103M -101M -4.48B
Net Debt -1.02B -898M -829M -766M -1.45B -98.04B -1.48B -9.97B -3.87B -47.98B -3.85B -3.76B -167B -1.31B -1.15B -1.06B -981M -1.86B -125B -1.9B -12.76B -4.96B -61.41B -4.92B -4.81B -213B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-07-09 US$280.92 +2.38% 177,114
26-07-08 US$274.39 -2.45% 1,398,594
26-07-07 US$281.27 -0.89% 1,759,681
26-07-06 US$283.80 +1.60% 1,358,559
26-07-02 US$279.32 +1.10% 1,274,247
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
274.39USD
Average target price
268.38USD
Spread / Average Target
-2.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock